Nose

Microbix Unveils Test Controls for Head and Neck Cancer

Retrieved on: 
Monday, March 11, 2024

While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer in other bodily tissues.

Key Points: 
  • While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer in other bodily tissues.
  • Such further types of HPV-driven cancer include those of the “Head and Neck,” collectively tumours inside and behind the nose, throughout the mouth (including the tongue, gums, and palate), all sections of the throat, and the voice box.
  • Unfortunately, a lack of standardized and reproducible reference samples makes it challenging to control the recommended test workflows for diagnosing such cancers.
  • These standardized and reproducible tissue-oriented test controls will then be added to Microbix’s catalogue of QAPs, expanding its activities into support of oncology workflows alongside its wide range of infectious disease test controls.

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, March 7, 2024

YARDLEY, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2023, and provided recent operational highlights.

Key Points: 
  • In addition, during 2023 we worked hard to prepare our organization to make the most of the new opportunity.
  • For the three-month and twelve-month periods ended December 31, 2023, research and development expenses were $1.3 million and $5.3 million, respectively.
  • The net loss for the three-month period ended December 31, 2023 was $10.0 million, or $0.09 per share (basic and diluted).
  • The net loss for the twelve-month period ended December 31, 2023 was $35.5 million, or $0.32 per share (basic and diluted).

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024

YARDLEY, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2023 and corporate updates, before market open on Thursday, March 7, 2024.

Key Points: 
  • YARDLEY, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2023 and corporate updates, before market open on Thursday, March 7, 2024.
  • Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates.
  • The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, March 7, 2024.
  • In addition, a replay of the webcast will be available on the Company website for 60 days following the event.

ImmunoLytics: Plan Ahead for Spring Allergy Season

Retrieved on: 
Thursday, February 29, 2024

Albuquerque, NM, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spring is just around the corner, and for approximately 81 million people, that means allergy season.

Key Points: 
  • Albuquerque, NM, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spring is just around the corner, and for approximately 81 million people, that means allergy season.
  • If allergy sufferers also have mold sensitivity, that will exacerbate the situation.
  • To better prepare for the upcoming spring allergy season, people should test their homes to see if there is a mold issue.
  • ImmunoLytics Mold Check-Up™ costs $36 per room and is analyzed by the company’s lab team that looks for 37,000 species of mold.

Early warm weather leads to early pollen count, Western Maryland health system allergy specialist says

Retrieved on: 
Monday, February 26, 2024

Paul Mauriello, M.D., with Meritus Allergy & Asthma Specialists said he found tree pollen when checking his air sampler on Feb. 12.

Key Points: 
  • Paul Mauriello, M.D., with Meritus Allergy & Asthma Specialists said he found tree pollen when checking his air sampler on Feb. 12.
  • “It’s a couple weeks early, by my records.”
    The reason for the early pollen count has to do with the environment, he said.
  • “Just a few nights of warmer weather, you'll have enough to get going.”
    Fortunately for allergy sufferers, the snow that fell in the following days cooled off the pollen production.
  • Meritus Allergy & Asthma Specialists sees the majority of its patients related to spring pollen, Dr. Mauriello said.

Modiv Industrial Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, March 4, 2024

Modiv Industrial, Inc. (“Modiv Industrial”, “Modiv”, the “Company”, “we” or “our”) (NYSE:MDV), the only public REIT exclusively focused on acquiring industrial manufacturing real estate, today announced operating results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Modiv Industrial, Inc. (“Modiv Industrial”, “Modiv”, the “Company”, “we” or “our”) (NYSE:MDV), the only public REIT exclusively focused on acquiring industrial manufacturing real estate, today announced operating results for the fourth quarter and full year ended December 31, 2023.
  • Fourth quarter revenue of $12.3 million increased $2.3 million year-over-year, or 23%, excluding the 2022 lease termination fee.
  • Fourth quarter AFFO of $4.5 million, or $0.40 per diluted share, exceeding street expectations by $0.05 per share.
  • January 31, 2024, completed the stock distribution of Generation Income Properties, Inc. (NASDAQ: GIPR), common stock to the stockholders of Modiv Industrial.

Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

Retrieved on: 
Friday, March 1, 2024

VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of atopic dermatitis (AD).

Key Points: 
  • VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of atopic dermatitis (AD).
  • VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. and is the same strength and formulation being studied in the ADORING Phase 3 development program for AD.
  • The following posters will be viewable onsite at the San Diego Convention Center.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

New Two-Year Results Show Sustained Improvement in Chronic Rhinitis Symptoms Following a Single Procedure with Aerin Medical’s RhinAer®

Retrieved on: 
Thursday, February 29, 2024

These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years.

Key Points: 
  • These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years.
  • These findings build on the previously published results of two separate studies that also demonstrated significant, sustained improvement with RhinAer treatment.1,2
    This press release features multimedia.
  • More than 87% of patients responded to treatment and patients showed sustained improvement in chronic rhinitis symptoms at two years.
  • Chronic rhinitis, when symptoms last more than four consecutive weeks, can be challenging to treat and may significantly lower a person’s quality of life.

Oticon Names Winners of the 25th Annual Oticon Focus on People Awards

Retrieved on: 
Thursday, February 29, 2024

Oticon, Inc. announced the winners of the Oticon Focus on People Awards , a national awards program celebrating outstanding advocates, hearing care professionals and everyday heroes who make a positive impact on the hearing loss community.

Key Points: 
  • Oticon, Inc. announced the winners of the Oticon Focus on People Awards , a national awards program celebrating outstanding advocates, hearing care professionals and everyday heroes who make a positive impact on the hearing loss community.
  • As a high school senior, he founded 3 Tiny Bones, a nonprofit focused on destigmatizing hearing loss and educating people on healthy hearing.
  • In addition, eligible first-place winners with hearing loss in the Student Standouts, Adult Trailblazers and Hearing Loss Champions categories received a pair of Oticon hearing aids.
  • Established in 1997, the Oticon Focus on People Awards program has honored more than 300 outstanding individuals throughout the United States.

World's First C919 Jet Owned by China Eastern Airlines Completes First Overseas Debut

Retrieved on: 
Wednesday, February 28, 2024

The world's first C919 aircraft, with the registration number B-919A and owned by China Eastern Airlines, wrapped up its first international debut at the Singapore Airshow on Feb. 26.

Key Points: 
  • The world's first C919 aircraft, with the registration number B-919A and owned by China Eastern Airlines, wrapped up its first international debut at the Singapore Airshow on Feb. 26.
  • During the 6-day Singapore Airshow, China Eastern Airline's C919 was mainly displayed statically.
  • It marked the first time for the aircraft to fly overseas and make its overseas airshow debut.
  • The C919 aircraft was also acclaimed as "one of the most anticipated products" at the Singapore Airshow this time.